Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.34 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.34 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.33 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | GRM5 | P41594 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.31 |
| ▸ | NEK7 | Q8TDX7 | 1/20 | 0.30 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27217806 | 0.96 | USP30 (0.36) | USP30BACE1BACE2CPB2GPR119 | |
| SCHEMBL30813573 | 0.90 | USP30 (0.38) | USP30BACE1BACE2CPB2AAK1 | |
| SCHEMBL27217825 | 0.86 | USP30 (0.36) | USP30BACE1BACE2 | |
| SCHEMBL30813412 | 0.82 | GPR119 (0.37) | CPB2GPR119GRM1GRM5NEK7 | |
| SCHEMBL30813487 | 0.79 | USP30 (0.44) | USP30BACE1BACE2AAK1 | |
| SCHEMBL30813409 | 0.78 | USP30 (0.39) | USP30BACE1BACE2AAK1 | |
| SCHEMBL21221307 | 0.78 | USP30 (0.39) | USP30BACE1BACE2NEK7 | |
| SCHEMBL27217939 | 0.78 | GPR119 (0.36) | CPB2GPR119GRM1GRM5PI4KA | |
| SCHEMBL29998475 | 0.78 | USP30 (0.39) | USP30BACE1BACE2AAK1 | |
| SCHEMBL30813583 | 0.76 | USP30 (0.38) | USP30BACE1BACE2AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. | 2024-05-16 | — | — | US | disclosed |
| WO-2024059200-A1 | NEK7 INHIBITORS | Halia Therapeutics, Inc. (US) | 2024-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158394-A1 | NEK7 INHIBITORS | NEK7, NEK5, NEK1 | USP30 1845/4885BACE1 207/4885BACE2 764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.